Cargando…
Antibody therapies for the prevention and treatment of viral infections
Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627241/ https://www.ncbi.nlm.nih.gov/pubmed/29263875 http://dx.doi.org/10.1038/s41541-017-0019-3 |
_version_ | 1783268678083543040 |
---|---|
author | Salazar, Georgina Zhang, Ningyan Fu, Tong-Ming An, Zhiqiang |
author_facet | Salazar, Georgina Zhang, Ningyan Fu, Tong-Ming An, Zhiqiang |
author_sort | Salazar, Georgina |
collection | PubMed |
description | Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline. |
format | Online Article Text |
id | pubmed-5627241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-56272412017-12-20 Antibody therapies for the prevention and treatment of viral infections Salazar, Georgina Zhang, Ningyan Fu, Tong-Ming An, Zhiqiang NPJ Vaccines Review Article Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline. Nature Publishing Group UK 2017-07-10 /pmc/articles/PMC5627241/ /pubmed/29263875 http://dx.doi.org/10.1038/s41541-017-0019-3 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Salazar, Georgina Zhang, Ningyan Fu, Tong-Ming An, Zhiqiang Antibody therapies for the prevention and treatment of viral infections |
title | Antibody therapies for the prevention and treatment of viral infections |
title_full | Antibody therapies for the prevention and treatment of viral infections |
title_fullStr | Antibody therapies for the prevention and treatment of viral infections |
title_full_unstemmed | Antibody therapies for the prevention and treatment of viral infections |
title_short | Antibody therapies for the prevention and treatment of viral infections |
title_sort | antibody therapies for the prevention and treatment of viral infections |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627241/ https://www.ncbi.nlm.nih.gov/pubmed/29263875 http://dx.doi.org/10.1038/s41541-017-0019-3 |
work_keys_str_mv | AT salazargeorgina antibodytherapiesforthepreventionandtreatmentofviralinfections AT zhangningyan antibodytherapiesforthepreventionandtreatmentofviralinfections AT futongming antibodytherapiesforthepreventionandtreatmentofviralinfections AT anzhiqiang antibodytherapiesforthepreventionandtreatmentofviralinfections |